In this article, we describe a variety of approaches used for modulation of cytokine responses to control arthritis (Figure 2, Table 1 and Table 2) and the properties of relatively newer cytokines (IL-32, IL-34, and IL-35), which have shown association with RA pathology and are being tested for their use in arthritis therapy in experimental models of RA. This evidence concerns the gene IL32 and rheumatoid arthritis.